- Home
- SCYX vs SGRP Comparison
SCYX vs SGRP Comparison
Compare SCYX & SGRP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCYX
- SGRP
- Stock Information
- Founded
- SCYX 1999
- SGRP 1967
- Country
- SCYX United States
- SGRP United States
- Employees
- SCYX N/A
- SGRP N/A
- Industry
- SCYX Biotechnology: Pharmaceutical Preparations
- SGRP Business Services
- Sector
- SCYX Health Care
- SGRP Consumer Discretionary
- Exchange
- SCYX Nasdaq
- SGRP Nasdaq
- Market Cap
- SCYX 50.3M
- SGRP 52.3M
- IPO Year
- SCYX 2014
- SGRP 1996
- Fundamental
- Price
- SCYX $1.02
- SGRP $1.88
- Analyst Decision
- SCYX Buy
- SGRP
- Analyst Count
- SCYX 1
- SGRP 0
- Target Price
- SCYX N/A
- SGRP N/A
- AVG Volume (30 Days)
- SCYX 210.1K
- SGRP 155.3K
- Earning Date
- SCYX 11-06-2024
- SGRP 12-31-2024
- Dividend Yield
- SCYX N/A
- SGRP N/A
- EPS Growth
- SCYX N/A
- SGRP N/A
- EPS
- SCYX N/A
- SGRP 0.50
- Revenue
- SCYX $8,566,000.00
- SGRP $228,869,000.00
- Revenue This Year
- SCYX N/A
- SGRP N/A
- Revenue Next Year
- SCYX $405.82
- SGRP N/A
- P/E Ratio
- SCYX N/A
- SGRP $3.80
- Revenue Growth
- SCYX N/A
- SGRP N/A
- 52 Week Low
- SCYX $0.90
- SGRP $0.95
- 52 Week High
- SCYX $3.07
- SGRP $3.12
- Technical
- Relative Strength Index (RSI)
- SCYX 34.82
- SGRP 37.92
- Support Level
- SCYX $0.90
- SGRP $1.82
- Resistance Level
- SCYX $1.04
- SGRP $1.99
- Average True Range (ATR)
- SCYX 0.07
- SGRP 0.10
- MACD
- SCYX -0.01
- SGRP 0.00
- Stochastic Oscillator
- SCYX 34.10
- SGRP 32.73
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
About SGRP SPAR Group Inc.
SPAR Group Inc is a supplier of merchandising and other marketing services. It also provides range of services to retailers, consumer goods manufacturers and distributors around the globe. The company divides its operations into three reportable regional segments: Americas, which is comprised of United States, Canada, Brazil and Mexico; Asia-Pacific (APAC), which is comprised of Japan, China, and India; and Europe, Middle East and Africa (EMEA), which is comprised of South Africa. It generates maximum revenue from Americas.